The abstract is read at the publisher; the summary is JClub's.
In EPIDAURUS, a 1-month DOAC plus potent P2Y12 inhibitor regimen (prasugrel or ticagrelor) in atrial fibrillation plus acute coronary syndrome was linked to higher bleeding rates in 602 enrolled patients.
- Why it matters: Choosing an optimal antithrombotic regimen for atrial fibrillation with acute coronary syndrome is difficult because dual therapy can reduce bleeding yet may increase ischemic events early after treatment starts.
- What they did: In an open-label randomized trial, 602 patients were assigned to DOAC plus potent P2Y12 inhibitor versus DOAC plus clopidogrel with in-hospital aspirin, with efficacy and safety assessed 6 weeks after randomization using win-loss ratio analyses.
- The result: The trial was stopped early for safety concerns, and exploratory bleeding analyses (BARC bleeding type ≥2 and ≥3) showed more bleeding with potent P2Y12 inhibitors without a clear ischemic benefit, arguing against routine use in this population.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.